ZNTL Matrix Capital Management Company LP sells $10.0M worth of shares
Dec 16, 2025, 5:37 AM
0.00%
What does ZNTL do
Zentalis Pharmaceuticals, a San Diego-based clinical-stage biopharmaceutical company, develops novel small molecule therapeutics for cancer, including WEE1 inhibitor azenosertib and BCL-2 inhibitor ZN-d5. The company went public on April 3, 2020, and employs 168 people.
Matrix Capital Management Company LP sold 7,500,000 shares of ZNTL on 15 December at $1.33 per share, worth a total of $10.0M. They now own 6,459,973 ZNTL shares, or a 54% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.